Elizabeth M. Jaffee

Cytokine gene-modified cell-based cancer vaccines.

Focus on pancreas cancer.

Pancreatic cancer.

To live or not to live: that depends on GAGE?

Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo.

Cytokine modified tumor vaccines.

Identification and characterization of the immunodominant rat HER-2/neu MHC class I epitope presented by spontaneous mammary tumors from HER-2/neu-transgenic mice.

Major histocompatibility complex class II-restricted presentation of a cytosolic antigen by autophagy.

Lentivirus-mediated gene transfer and expression in established human tumor antigen-specific cytotoxic T cells and primary unstimulated T cells.

HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic mice.

Cancer vaccines: an old idea comes of age.

Toward a breast cancer vaccine: work in progress.

Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients.

Fatty acid synthase inhibitors are chemopreventive for mammary cancer in neu-N transgenic mice.

Development of a cytokine-modified allogeneic whole cell pancreatic cancer vaccine.

Augmenting the potency of breast cancer vaccines: combined modality immunotherapy.

Tumor-specific CD4+ T cells from a patient with renal cell carcinoma recognize diverse shared antigens.

Diverse CD8+ T-cell responses to renal cell carcinoma antigens in patients treated with an autologous granulocyte-macrophage colony-stimulating factor gene-transduced renal tumor cell vaccine.

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response.

Immunotherapy for pancreatic cancer - science driving clinical progress.

Allergies and the risk of pancreatic cancer: a meta-analysis with review of epidemiology and biological mechanisms.

Fusion to Listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse.

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy.

Cancer vaccines in combination with multimodality therapy.

Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology.

OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigen.

Cancer immunologists and cancer biologists: why we didn't talk then but need to now.

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism.

Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice.

Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a Pre-Barrett's esophagus setting.

Alteration of cellular and humoral immunity by mutant p53 protein and processed mutant peptide in head and neck cancer.

Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.

Vaccine impedes the development of reflux-induced esophageal cancer in a surgical rat model: efficacy of the vaccine in a post-Barrett's esophagus setting.

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

Core signaling pathways in human pancreatic cancers revealed by global genomic analyses.

Use of tumour-responsive T cells as cancer treatment.

Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene.

Genetic mutations associated with cigarette smoking in pancreatic cancer.

OX40 costimulation can abrogate Foxp3+ regulatory T cell-mediated suppression of antitumor immunity.

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation.

Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice.

Effective depletion of regulatory T cells allows the recruitment of mesothelin-specific CD8 T cells to the antitumor immune response against a mesothelin-expressing mouse pancreatic adenocarcinoma.

Cellular vaccine approaches.

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.

CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response.

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response.

Review of the 25th annual scientific meeting of the International Society for Biological Therapy of Cancer.

Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer.

Increased expression of DNA repair genes in invasive human pancreatic cancer cells.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Defining the critical hurdles in cancer immunotherapy.

Trafficking of high avidity HER-2/neu-specific T cells into HER-2/neu-expressing tumors after depletion of effector/memory-like regulatory T cells.

The determinants of tumour immunogenicity.

Development of a novel preclinical pancreatic cancer research model: bioluminescence image-guided focal irradiation and tumor monitoring of orthotopic xenografts.

Whole cell vaccines--past progress and future strategies.

Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.

Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective.

Concomitant targeting of tumor cells and induction of T-cell response synergizes to effectively inhibit trastuzumab-resistant breast cancer.

Targeting the right regulatory T-cell population for tumor immunotherapy.

Vaccines for pancreatic cancer.